Depression News

AbbVie has submitted a supplemental new drug application for Vraylar to the FDA for the adjunctive treatment of major depressive disorder in patients receiving ongoing antidepressant therapy, according to a press release.

Agomelatine proved safe and effective in treating adolescents with major depressive disorder who received psychosocial counseling, according to a double-blind randomized controlled phase 3 trial published in Lancet Psychiatry.

Women who participated in music therapy had lower levels of depression and reduced menopausal symptoms compared with those who did not, according to findings in Menopause.

Patients with mood or anxiety disorders had significant rates of PTSD, depressive and anxiety symptoms that often persisted beyond 3 months following lockdown for the COVID-19 pandemic, according to study results.

Veterans who survived COVID-19 were at increased risk for mental health, substance use and sleep disorders up to 1 year later, data showed.

Adults with two or more chronic conditions by middle age had an increased risk for dementia later in life, according to findings published in The BMJ.

Combination therapy that included an antagonist of presynaptic alpha2-autoreceptors appeared effective and safe for patients with depression who did not respond to monotherapy, according to a report published in JAMA Psychiatry.

Psychological pain is linked with levels of physical pain and recent suicidal acts, as well as depression symptom severity, according to a French study published in the Journal of Clinical Psychiatry.

Mindfulness-based interventions may ease burnout, increase compassion and improve the patient-physician relationship, according to a presentation at Healing Healthcare: A Global Mindfulness Summit.

The Patient Health Questionnaire-9 appeared reliable and valid for depression screening among patients with neurological disorders, according to study results published in BMC Psychiatry.